Summary of the 9 patients who relapsed after rituximab treatment
Patient no. . | Age . | Sex . | Stage/restage . | Initial response to rituximab . | FFP, mo . | Histology at progression . | Treatment . | Response . |
|---|---|---|---|---|---|---|---|---|
| Not previously treated | ||||||||
| 1 | 60 | M | IIIA | PR | 10 | TCR-BCL | CHOP | Responding |
| 2 | 23 | M | IIIA | PR | 9 | LPHD | Rituximab | SD (4.5 mo) |
| 3 | 38 | F | IA | PR | 6 | ND | Observation | NA |
| 4 | 45 | M | IA | PR | 10 | ND | Observation | NA |
| 5 | 32 | M | IIIA | PR | 7.5 | LPHD | Rituximab | SD (16.5 mo)* |
| 6 | 46 | F | IIIA | CR | 14 | ND | Observation | NA |
| Previously treated | ||||||||
| 7 | 51 | M | IIIA | CR | 12 | ND | Observation | NA |
| 8 | 25 | M | IIA | PR | 7.5 | LPHD | Rituximab | CR (11 mo) |
| 9 | 29 | M | IIA | PR | 8.5 | DLBCL | Rituximab followed by CHOP | CR (12 mo) |
Patient no. . | Age . | Sex . | Stage/restage . | Initial response to rituximab . | FFP, mo . | Histology at progression . | Treatment . | Response . |
|---|---|---|---|---|---|---|---|---|
| Not previously treated | ||||||||
| 1 | 60 | M | IIIA | PR | 10 | TCR-BCL | CHOP | Responding |
| 2 | 23 | M | IIIA | PR | 9 | LPHD | Rituximab | SD (4.5 mo) |
| 3 | 38 | F | IA | PR | 6 | ND | Observation | NA |
| 4 | 45 | M | IA | PR | 10 | ND | Observation | NA |
| 5 | 32 | M | IIIA | PR | 7.5 | LPHD | Rituximab | SD (16.5 mo)* |
| 6 | 46 | F | IIIA | CR | 14 | ND | Observation | NA |
| Previously treated | ||||||||
| 7 | 51 | M | IIIA | CR | 12 | ND | Observation | NA |
| 8 | 25 | M | IIA | PR | 7.5 | LPHD | Rituximab | CR (11 mo) |
| 9 | 29 | M | IIA | PR | 8.5 | DLBCL | Rituximab followed by CHOP | CR (12 mo) |
FFP indicates freedom from progression; M, male; PR, partial response; TCR-BCL, T-cell—rich B-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; LPHD, lymphocyte-predominant Hodgkin disease; SD, stable disease; F, female; ND, not done; NA, not applicable; CR, complete response; and DLBCL, diffuse large B-cell lymphoma.
Progressive disease at 16.5 months.